Caidya vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Caidya is a global mid-sized CRO formed from the merger of dMed Global and Clinipace; operates in 20+ countries across 50+ regions; raised $165M from Rubicon Founders in January 2025;
About
Caidya is a global, full-service contract research organization (CRO) formed in 2021 through the merger of dMed Global, a Shanghai-based clinical research firm, and Clinipace Incorporated, a North Carolina-based CRO. The combined entity rebranded as Caidya with a mission to "liberate clinical research" by providing more personalized, knowledge-driven CRO services to biopharmaceutical innovators developing breakthrough therapies for patients with unmet medical needs. Headquartered in Raleigh, North Carolina, Caidya operates across more than 20 countries with study execution capabilities spanning more than 50 countries and regions — including deep expertise in the Americas, Europe, and Asia-Pacific, particularly Mainland China.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.